Here, we investigated the therapeutic potential of NU7441, a novel specific inhibitor of DNA-PKcs, in H460 (K-Ras mutation), A549 (K-Ras mutation) and H1299 (N-Ras mutation and p53 null) NSCLC cells. Here, KRAS is linked to non-small cell lung carcinoma.